Age and Therapy Changes Shape MS Transition Paths

Scientists examined the shift from relapsing‑remitting MS to a steady form. They used data from a long‑term study that followed adults with MS for many years. The goal was to see what factors predict this change.

Out of 565 patients, 97 moved into the steady phase. Most of those, about 90, had no new attacks in the two years before the switch. These were labeled non‑relapsing secondary progressive. The average age of these patients was roughly 53 years. In contrast, those who had recent attacks were about 45 years old. The time to reach the steady phase was longer, around 13 years, compared with less than 8 years for the other group.

Older age when MS first appeared and a high number of therapy changes were linked to a quicker move to the steady phase. Statistical tests showed these links were strong, with p‑values below 0.001. This means age and treatment switching matter a lot for how fast disability progresses.

Doctors can use this information to watch patients more closely and adjust therapy before disability builds up. The study highlights that monitoring age and therapy patterns helps target treatment early. Overall, the research gives a clearer picture of how MS evolves and what to watch for.